BeOne Medicines (ONC) Notes Payables (2017 - 2025)

BeOne Medicines' (ONC) quarterly Notes Payables came in at $813.3 million in Q3 2025, down 4.49% on a QoQ basis from $851.5 million in Q4 2024.

BeOne Medicines (ONC) Notes Payables (2017 - 2025) Analysis & Trends

BeOne Medicines (ONC) has 4 years of Notes Payables data on file, last reported at $813.3 million in Q3 2025.

On a quarterly basis, Notes Payables changed N/A year-over-year to $813.3 million in Q3 2025; TTM through Sep 2025 was $813.3 million, a N/A change from a year earlier, with the FY2024 full-year figure at $851.5 million, changed N/A from the prior year.
Notes Payables for Q3 2025 stood at $813.3 million, down from $851.5 million in the prior quarter.
Over the last five years, Notes Payables for ONC reached as high as $851.5 million in Q4 2024 and fell as low as $813.3 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn

Download Data